KROS vs BEAM vs IMVT vs EDIT

For growth investors, Keros Therapeutics, Inc.

(KROS) is the stronger pick with 67. 7% revenue growth year-over-year, versus -100. 0% for Editas Medicine, Inc. (EDIT). Keros Therapeutics, Inc. (KROS) offers the better valuation at 5. 2x trailing P/E, making it the more compelling value choice. Analysts rate Keros Therapeutics, Inc. (KROS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +84. 4%, compared to -90. 1% for Editas Medicine, Inc. (EDIT). Over 10 years, the gap is even starker: IMVT returned +190. 9% versus EDIT's -89. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Keros Therapeutics, Inc.

(KROS) is the lower-risk stock at 1. 00β versus Editas Medicine, Inc. 's 2. 45β — meaning EDIT is approximately 145% more volatile than KROS relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 66% for Editas Medicine, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Keros Therapeutics, Inc.

(KROS) is pulling ahead at 67. 7% versus -100. 0% for Editas Medicine, Inc. (EDIT). On earnings-per-share growth, the picture is similar: Keros Therapeutics, Inc. grew EPS 146. 0% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Keros Therapeutics, Inc.

(KROS) is the more profitable company, earning 35. 7% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 35. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KROS leads at 28. 9% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — KROS leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Keros Therapeutics, Inc.

(KROS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00)). Editas Medicine, Inc. (EDIT) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KROS: -39. 9%, EDIT: -89. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KROS is a small-cap high-growth stock; BEAM is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; EDIT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.